LQDA · Liquidia Corp
Market Cap
$6.06B
Shares
89.51M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$67.69
Open$69.99
Day$67.57–70.31
52W close$21.80–91.03
Avg vol 30d1.5M
Short int11.9M · 13.2% float · 6.5d
Short vol54%
Last earningsAug 12, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 8, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+34%
above
Price vs 50-day avg
−14%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
66%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−20%
trailing
6-month return
+89%
trailing
YTD return
+96%
this year
Relative strength
+75%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $79 › 200d $50 — 50d above 200d
Institutional flow
Accumulating
+35% holders QoQ · +128 funds added
Insider flow
Distributing
Net -$119.7M over 90 days · 100% sells
Short interest
Falling
13.25% of float · ▼ -0.9% MoM · 6.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
340 holders — near 3-yr high, broad support
Squeeze score
61
elevated · 0–100
Fundamentals
Revenue growth
+1031%
Y/Y
EPS growth
+51%
Y/Y
Free cash flow
$-40.0M
Balance sheet
$73.4M
net cash
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−36%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
At least $1 billion in revenue
· 2027
at least $1B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+34%
Bullish
Price vs 50-day avg
−14%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
66%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $79 › 200d $50 — 50d above 200d
Institutional flow
Accumulating
+35% holders QoQ · +128 funds added
Insider flow
Distributing
Net -$119.7M over 90 days · 100% sells
Short interest
Falling
13.25% of float · ▼ -0.9% MoM · 6.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
340 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $22
Now $68 · 66%
Range high $91
vs 200-day avg +34%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $96.3M | the second quarter of 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net income 74.72M
+3.82M Interest expense, net
+6.98M Income tax expense
+400K Depreciation and amortization
+10.37M Stock-based compensation
= Adjusted EBITDA 96.29M
|
|||
| Cash Balance | $284.2M | Q2 2026 | — |
| Net product sales | $170.4M | Q2 2026 | +2514.7% |
|
|
|||
| Net product sales annualized run-rate | $682M | Q2 2026 | — |
| Patients started on treatment since launch | 5,000 | as of July 31, 2026 | — |
| Prescribers | 1,100 | as of July 31, 2026 | — |
| Total prescribers since launch | 1,100 | as of July 31, 2026 | — |
| Unique patient prescriptions since launch | 5,900 | as of July 31, 2026 | — |
| YUTREPIA net product sales | $170.4M | the second quarter of 2026 | +2514.7% |
|
|
|||
| patients treated | 3,750 | since launch in June 2025 through April 30, 2026 | — |
| prescribers that have prescribed YUTREPIA to at least 5 patients | 270 | as of April 30, 2026 | — |
| Unique prescribers since launch | 980 | since launch through April 30, 2026 | — |
| patients started on treatment | 2,900 | since launch as of February 28, 2026 | — |
| total prescribers | 860 | as of February 28, 2026 | — |
| unique patient prescriptions | 3,600 | since launch as of February 28, 2026 | — |
| unique prescriptions received | 3,600 | since launch in June 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LQDA
this stock
Liquidia Corp
|
$6.06B | +96.3% | +1031.2% | — | 13.2% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.59B | +15.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.38B | +2.2% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.46B | +0.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LQDA | -1.4% | -19.5% | +88.7% | -19.5% | +96.3% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -1.8% | -22.5% | +75.3% | -22.5% | +83.4% |
Key facts
CIK
1819576
CUSIP
53635D202
13F (30d)
274 filings
271 filers
Visit website
Investor relations